Summary of Key Points Core Viewpoint - BGI Genomics (300676) has announced the approval of a foreign exchange hedging business for the year 2026 during its second extraordinary general meeting of shareholders held on November 12, 2025, indicating a strategic move to manage currency risk effectively [1]. Financial Performance - As of the market close on November 13, 2025, BGI Genomics' stock price was 49.18 yuan, reflecting a decrease of 0.65% from the previous trading day [1]. - The company's total market capitalization stood at 20.573 billion yuan, with a trading volume of 2.52 billion yuan and a turnover rate of 1.24% on the same day [1]. Shareholder Meeting Details - The extraordinary general meeting was conducted using a combination of in-person and online voting, with shareholder representatives holding 39.1127% of the total voting rights present [1]. - The legal opinion regarding the meeting was provided by Guohao Law Firm (Shenzhen), confirming the legality and validity of the meeting's convening, procedures, and voting results [1].
华大基因(300676)披露2026年度开展外汇套期保值业务计划,11月13日股价下跌0.65%